MuGard is designed to manage oral mucositis by forming a protective hydrogel coating over the oral mucosa to shield the membranes of the mouth and tongue.
PlasmaTech Biopharmaceuticals CEO Scott Schorer said: "Access is pleased to announce this additional partnership with Norgine, a leading European specialty company, as it further validates our MuGard global growth strategy.
"With strong international presence, an existing supportive cancer care product portfolio and commitment to providing cancer patients with effective treatments, Norgine is an ideal partner to have as we enter new markets, like Australia and New Zealand."
Terms of the agreement are similar to PlasmaTech’s recent license with Norgine for MuGard in Europe.
As part of the deal, Norgine will now develop, manufacture and commercialize MuGard in the new territories.
Oral mucositis is a common side effect of cancer treatments, which has affected about 400,000 individuals in the US alone.